Skip to main
  1. Stocks
  2. Bausch + Lomb Corp
  3. Forecast
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 36%
Hold 45%
Sell 0%
Strong Sell 0%

Bulls say

Bausch & Lomb is attractive because its growth is increasingly led by differentiated, higher-margin franchises across all three segments, with MIEBO revenue up 42% year over year to $119M in 3Q26 and prescription dry eye up 22%, while premium IOLs and daily SiHy lenses are also taking share. Operationally, 3Q26 revenue of $1.375B was in line, but adjusted EBITDA of $325M beat expectations on 64.7% gross margin, disciplined SG&A and R&D, and management raised FY26 EBITDA guidance by $65M to $1.090B–$1.140B. The company also has adequate liquidity with $515M of cash and restricted cash against $5.095B of long-term debt, and the combination of margin expansion, product innovation, and disciplined capital allocation supports a constructive fundamental outlook.

Bears say

Bausch & Lomb is facing a weakened fundamental setup because leadership instability, with Brent Saunders’ departure, an interim CEO who also runs Bausch Health, and no announced permanent search, leaves strategy and execution clouded while BHC still controls about 87% of the shares and the float remains limited near 13%. Regulatory risk is also elevated after the FDA’s September Warning Letter on cGMP violations at the Tampa facility, even as remediation runs into later this year or early 2027, and that overhang adds uncertainty to production quality and investor confidence. Operationally, the business is vulnerable to under-scaled Surgical margins, potential softness in MIEBO and contact lens demand, and competitive and macro pressures, all of which could keep revenue and EBITDA growth below expectations.

BLCO has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 36% recommend Buy, 45% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

BLCO Analyst Forecast & Price Prediction

Get the latest BLCO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BLCO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Buy based on their latest research and market trends.

According to 11 analysts, BLCO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


BLCO Analyst Forecast & Price Prediction

Get the latest BLCO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BLCO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BLCO stock data and trends